2 results about "Moxifloxacin" patented technology

The application relates to a high-activity electrode and a preparation method thereof and application of the electrode in sewage treatment. The preparation method is as follows: Sn source, Sb source and Tb source are configured into a mixed solution, the Tb-Sn-Sb sol is obtained after ultrasonic treatment and standing and aging, the Tb-Sn-Sb sol is uniformly coated on the surface of an electrode substrate, and the high-activity titanium-based tin dioxide-antimony electrode is prepared through heat treatment at a specific temperature. The application finds that, for the first time, the rare earth element Tb is doped in the Ti / SnO2-Sb electrode, the conductivity of the Ti / SnO2-Sb electrode can be greatly improved, and the treatment capacity of the Ti / SnO2-Sb electrode for wastewater containing organic pollutants can be greatly improved. The removal rate of the Ti / SnO2-Sb-Tb electrode for moxifloxacin reaches more than 84%, while the removal rate of the conventional Ti / SnO2-Sb electrode for moxifloxacin is only 58.4%, and the removal rate of the Ti / SnO2-Sb-Ho electrode doped with other rare earth elements for moxifloxacin is 74.1%, which further shows that the doping of the rare earth element Tb in the Ti / SnO2-Sb electrode can greatly improve the treatment capacity of the electrode for wastewater containing organic pollutants.

This invention discloses the application of *Gastrococcus xanthophylloides* in regulating intestinal bile acid metabolism disorders, including *Gastrococcus xanthophylloides* (… Ruminococcus flavefaciens The application of this invention in the preparation of compositions for regulating intestinal bile acid metabolism disorders, wherein the compositions promote the conversion of primary bile acids to secondary bile acids, wherein the primary bile acids include cholic acid and chenodeoxycholic acid, and the secondary bile acids include deoxycholic acid and lithocholic acid; wherein the intestinal bile acid metabolism disorders include metabolic disorders caused by antibiotics, wherein the antibiotics include one or more of moxifloxacin and metronidazole; wherein the compositions can be health products, pharmaceuticals, or feed; and wherein the active ingredient of the compositions includes xanthospirococcus flavus.